At a glance
- Originator Roche
- Class Antiasthmatics; Heart failure therapies; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Psoriasis; Septic shock
Most Recent Events
- 23 Nov 1998 Discontinued-Clinical for Psoriasis in USA (Topical)
- 11 Mar 1998 Discontinued-Preclinical for Septic shock in USA (Unknown route)